Boehringer Ingelheim

SAFETY DATA SHEET

1. Identification

Product identifier ReproCyc ParvoFLEX

Other means of identification

Product code APHIS Code - 18P5.R0, Family Code - 760

Recommended use Veterinary vaccine.

Recommended restrictions For use in animals only. Not for human use.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer Boehringer Ingelheim Animal Health USA Inc.

Address 2621 North Belt Hwy

St. Joseph, MO 64506-2002

Transportation emergency For Chemical Emergency Spill, Leak, Fire, Exposure, or Accident Call CHEMTREC Day or

Nigh

Within USA and Canada: 1-800-424-9300

Outside USA and Canada: +1 703-527-3887 (collect calls accepted)

Medical Emergency

(24HR):

(888) 637-4251

Non-Emergency calls: (888) 637-4251

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.
Signal word None.

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

Prevention Observe good industrial hygiene practices.

Response Wash hands after handling.

Storage Keep at a temperature between 35 - 46°F (2 - 8°C).

Disposal Dispose of waste and residues in accordance with local authority requirements.

Hazard(s) not otherwise

classified (HNOC)

None known.

Supplemental information For animal injection only. Not for human use. Accidental human injection can cause serious local

reactions or anaphylactic reaction and systemic effects.

3. Composition/information on ingredients

Mixtures

Chemical name	CAS number	%
Porcine Parvovirus (PPV VP2) diafiltered inactivated fluids	-	Proprietary
Additives	-	Proprietary

Composition comments Contains neomycin as preservative.

The specific chemical identity and/or exact percentage of component(s) have been withheld as a

trade secret.

4. First-aid measures

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

ReproCyc ParvoFLEX SDS US

Skin contact Eye contact

Wash off with soap and water. Get medical attention if irritation develops and persists.

Rinse with water. Remove contact lenses, if present, after the first 5 minutes, then, continue rinsing eye. Get medical attention if irritation develops and persists.

Ingestion

Rinse mouth. Get medical attention if symptoms occur. Only induce vomiting at the instruction of

medical personnel. Never give anything by mouth to an unconscious person.

Most important

symptoms/effects, acute and

delayed

Swelling at injection site may occur. Accidental human injection can cause serious local reactions

or anaphylactic reaction and systemic effects.

Indication of immediate medical attention and special treatment needed

For animal injection only. Not for human use. Persons developing anaphylactic (life threatening) reactions, such as difficulty in breathing or unconsciousness, must receive immediate medical attention. Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed.

General information

Animals or persons developing anaphylactic (life-threatening) reactions, such as difficulty in breathing or unconsciousness, must receive immediate medical attention. If anaphylactoid reactions occur, epinephrine may be used as an antidote. If you feel unwell, seek medical advice (show the label where possible).

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed. Combustion products may include: carbon

monoxide, carbon dioxide, metal oxides.

Special protective equipment and precautions for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions Move containers from fire area if you can do so without risk.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions. protective equipment and emergency procedures

Keep unnecessary personnel away. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up Stop the flow of material, if this is without risk. Absorb in vermiculite, dry sand or earth and place into containers. Clean surface thoroughly to remove residual contamination. Decontaminate all wastes that contain or have come in contact with the infectious organism by autoclave, chemical disinfection, gamma irradiation, or incineration before disposing. For waste disposal, see section 13 of the SDS.

Environmental precautions

Should not be released into the environment. Do not discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid accidental injection. Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Use care in handling/storage.

Conditions for safe storage, including any incompatibilities Store locked up. Store in the dark at 35 - 46°F (2 - 8°C). Do not freeze. Shake well. Keep out of direct sunlight. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

No exposure limits noted for ingredient(s).

Biological limit values

Appropriate engineering controls

No biological exposure limits noted for the ingredient(s).

Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. Eyewash station and safety shower

are recommended.

Individual protection measures, such as personal protective equipment

Wear safety glasses with side shields (or goggles). Eye/face protection

Skin protection

Hand protection Impervious gloves should be used at all times when handling this product.

ReproCyc ParvoFLEX SDS US 2/6 Other Wear lab coat or other protective garments.

Respiratory protection Not generally required when handling vials or containers. In case of insufficient ventilation, wear

suitable respiratory equipment.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

9. Physical and chemical properties

Appearance

Physical state Liquid.

Form Combination of 2 products: Clear liquid and Lyophilized modified live virus supplied as a solid plug

with a solution of liquid diluent.

Color Clear yellowish liquid and White plug; After rehydration: Cloudy liquid

Odor Odorless.

Odor threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Vapor pressureNot available.Vapor densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.
(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Other information

Explosive properties Not explosive. **Oxidizing properties** Not oxidizing.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Heat. Freezing temperatures. Exposure to light. Contact with incompatible materials.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

ReproCyc ParvoFLEX SDS US

11. Toxicological information

Information on likely routes of exposure

Inhalation Mist/aerosols may cause respiratory tract irritation.

Prolonged skin contact may cause temporary irritation. Skin contact Direct contact with eyes may cause temporary irritation. Eve contact

Ingestion Ingestion may cause irritation and malaise. However, ingestion is not likely to be a primary route

of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics Swelling at injection site may occur. Accidental human injection can cause serious local reactions

or anaphylactic reaction and systemic effects.

Information on toxicological effects

Not expected to be acutely toxic. **Acute toxicity**

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation. Direct contact with eyes may cause temporary irritation. Serious eye damage/eye

irritation

Respiratory or skin sensitization

Respiratory sensitization Not a respiratory sensitizer.

Skin sensitization This product is not expected to cause skin sensitization.

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Carcinogenicity Not classifiable as to carcinogenicity to humans.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

NTP Report on Carcinogens

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Reproductive toxicity This product is not expected to cause reproductive or developmental effects.

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazard Not an aspiration hazard.

Further information Possible hypersensitization (development of abnormal sensitivity). This is an inactivated vaccine

and there should be no danger of reversion to virulence or potential for it to combine with field

strains.

12. Ecological information

The product is not classified as environmentally hazardous. However, this does not exclude the **Ecotoxicity**

possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Persistence and degradability No data is available on the degradability of this product.

Bioaccumulative potential No data available on bioaccumulation. Mobility in soil No data available for this product.

Other adverse effects Do not release into the environment. An environmental hazard cannot be excluded in the event of

unprofessional handling or disposal.

13. Disposal considerations

Disposal instructions Material must be decontaminated prior to disposal or be disposed of as a biohazard waste before

being released from the laboratory. Dispose of in accordance with local, state, federal, national or

international regulations for biohazardous materials.

Local disposal regulations Dispose in accordance with all applicable regulations.

The waste code should be assigned in discussion between the user, the producer and the waste Hazardous waste code

disposal company.

ReproCyc ParvoFLEX SDS US 4/6 Waste from residues / unused

products

Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Decontaminate all wastes that contain or have come in contact with the infectious organism by autoclave, chemical disinfection,

gamma irradiation, or incineration before disposing.

Contaminated packaging

Since emptied containers may retain product residue, follow label warnings even after container is emptied. Decontaminate before disposal: steam sterilization, incineration, chemical disinfection, or

autoclaved when applicable. Dispose in accordance with all applicable regulations.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Not established.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulations

This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON ORDER OF LICENSED

VETERINARIANS.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Toxic Substances Control Act (TSCA)

All components are either listed on the TSCA 8(b) inventory and

designated "active" or exempt from listing.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

Not listed.

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed.

ReproCyc ParvoFLEX SDS US

957540 Version #: 01 Revision date: - Issue date: 22-March-2021

US. Rhode Island RTK

Not regulated.

California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 2016 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins. For more information go to www.P65Warnings.ca.gov.

16. Other information, including date of preparation or last revision

Issue date 22-March-2021

Revision date Version # 01

Health: 0 **HMIS®** ratings

Flammability: 0 Physical hazard: 0

NFPA ratings



Disclaimer

The information provided herein is offered by Boehringer Ingelheim Animal Health USA Inc. (BI AH USA) in good faith as accurate as of the date hereof, but without guarantee. This information includes information which has been generated by other parties and provided to BI AH USA, and which BI AH USA has not independently verified. The information provided herein relates only to the specific product designated, and may not be valid where such product is used in combination with any other materials or in any process. The information provided herein is offered solely for your consideration, investigation and verification, and Boehringer Ingelheim Animal Health USA Inc. (BI AH USA) expressly disclaims all liability for reliance thereon. BI AH USA EXPRESSLY DISCLAIMS ALL WARRANTIES OF EVERY KIND AND NATURE (INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO THE USE OR SUITABILITY OF THE PRODUCT. In addition, since the conditions of use and suitability of the product for particular uses are beyond BI AH USA's control, ALL RISKS OF USE OF THE PRODUCT ARE THEREFORE ASSUMED BY THE USER, AND BI AH USA EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY AS TO ANY RESULTS OBTAINED OR ARISING FROM ANY USE OF THE PRODUCT. Use or transmission of the information contained herein in any other format than the format as presented is strictly prohibited. Nothing herein shall be construed as permission or recommendation for the use of the product in a manner that might infringe an existing patent. BI AH USA neither represents nor warrants that the format, content or product formulas contained in this document comply with the laws of any other country except the United States of America.

ReproCyc ParvoFLEX SDS US Issue date: 22-March-2021